Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Hope Bauer

Urogynecology and Reconstructive Pelvic Surgery Grand Rapids, MI Medical Doctor

NPI 1083108369 CMS profile 4480710

25 Michigan St Ne Ste 6200, Grand Rapids, MI 49503

Open in the dashboard

General payments

$4,944

60 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hope Bauer of Grand Rapids, MI is reported in the CMS Open Payments database as having received $4,944 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,890 18
2024 General $1,407 19
2023 General $994 17
2022 General $653 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hope Bauer
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Hope Bauer were reported at $1,890. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Hope Bauer Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $0 $358 $132–$1,270 $163
2020 $0 $198 $86–$642 $114
2021 $0 $361 $118–$1,182 $132
2022 $653 $410 $128–$1,175 $149
2023 $994 $434 $152–$1,344 $160
2024 $1,407 $494 $193–$1,331 $164
2025 $1,890 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $2,561 26 payments
  2. Axonics Modulation Technologies, Inc. $698 11 payments
  3. Caldera Medical, Inc $507 8 payments
  4. Medtronic, Inc. $188 1 payment
  5. Coloplast Corp $163 1 payment
  6. Davol Inc. $158 1 payment
  7. Bluewind Medical $131 2 payments
  8. AbbVie, Inc. $123 2 payments
  9. Sumitomo Pharma America, Inc. $114 2 payments
  10. Teleflex LLC $108 2 payments
  11. Other $194 4 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,766 53 payments
  2. Travel and Lodging $1,177 7 payments
Products named General payments · program years 2022–2025
  1. Axonics $2,356 26 payments
  2. Desara $507 8 payments
  3. Advantage System $476 5 payments
  4. Bulkamid $274 2 payments
  5. ARISTA AH FlexiTip $158 1 payment
  6. Upsylon $142 2 payments
  7. REVI $131 2 payments
  8. GEMTESA $114 2 payments
  9. SOLESTA $108 2 payments
  10. BOTOX $100 1 payment
  11. Other $503 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

169

Median for Obstetrics & Gynecology: 65

Drug cost

$13,649

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

20.1%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 12 $9,211
Estradiol Generic 33 $1,679
Solifenacin Succinate Generic 20 $1,070
Tolterodine Tartrate Er Tolterodine Tartrate Brand 11 $1,022
Oxybutynin Chloride Er Oxybutynin Chloride Brand 11 $343
Ketorolac Tromethamine Generic 11 $203
Ibuprofen Generic 24 $59
Tramadol Hcl Generic 27 $32
Oxycodone Hcl Generic 20 $30

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record